The Centers for Disease Control and Prevention (CDC) found that 700 women in the United States die each year as a result of pregnancy or pregnancy-related complications, and the rate has more than doubled since 1987. Pregnancy-related deaths per 100,000 live births rose from 7.2 nationally in 1987 to 17.3 in 2013, peaking at 17.8 in 2009 and 2011. In Connecticut, there were eight pregnancy-related deaths from 2011 to 2014. But there’s no data available yet for the years since 2014 and at the moment there are precious few dollars devoted to accessing it
For more on this story by Christine Stuart of ctnewsjunkie.com click here.
A new study—the largest of its kind—says that women who are diagnosed with the most common type of early-stage breast cancer most likely don’t need chemotherapy after they’ve had endocrine (hormone) therapy. The news could lay to rest some anguished conversations between doctors and patients. When a woman is diagnosed with breast cancer, all medical muscle goes toward eliminating the cancer and reducing the possibility of a recurrence. But for many women, chemotherapy can have disastrous results. This study says that if the additional treatment isn’t necessary—or has little measurable positive effect—many women can skip it.
A growing number of reproductive-age women are taking prescription medication to treat attention-deficit/hyperactivity disorder (ADHD), data show, but doctors warn the effects of such drugs on pregnancies are largely unknown. The number of privately insured women nationwide between the ages of 15 and 44 who filled a prescription for an ADHD medication soared 344 percent from 2003 to 2015, from 0.9 percent to 4 percent, according to Centers for Disease Control and Prevention (CDC). ADHD medication use increased among all age brackets within that group and in all geographic regions, data show. The biggest spikes were seen in women ages 25 to 29, among which medication use jumped 700 percent, from 0.5 percent in 2003 to 4 percent in 2015. The second-largest increase was among women ages 30 to 34, which had a 560 percent increase from 0.5 percent to 3.3 percent, according to the CDC.
During the recent Women’s March in Hartford, Susan Eastwood, a board member of the nonprofit Permanent Commission on the Status of Women in CT, wandered among attendees and asked them about paid family leave. First, she asked women pushing strollers—ostensibly, women in their child-bearing years. They told her compelling stories about not having enough money to take time off from work. But the older women were particularly passionate. They are caring for elderly parents, for adult children with significant medical needs, or they’re batting their own health issues.
An ever-increasing number of women in the state are drinking to excess, state and federal data show. Statewide, female admissions to acute hospital emergency departments for alcohol-related reasons rose by 4.8 percent between fiscal years 2012 and 2016, according to the Connecticut Hospital Association. The female-only Eden Hill Recovery Retreat in Canaan fills an average of 10 to 12 beds per month; earlier in the center’s eight-year history, rarely were there more than eight beds occupied at a time. Researchers at the Yale School of Medicine note an increase in the number of women enrolling in studies that examine the effectiveness of a medication to curb one’s desire to drink alcohol. The uptick in problem drinking among women in Connecticut mirrors a national trend.
In October, President Donald Trump announced new regulations that loosen the requirements that employers provide coverage for contraceptives, which was a pillar of the Affordable Care Act (Obamacare). Trump’s government expanded the reasons an employer could skip out on coverage on moral or religious objections. If in the recent weeks your employer just got religion, you should know why. Trump is messing with a woman’s important right to accessible and affordable birth control. The birth control mandate, according to the Kaiser Family Foundation, “had a large impact in a short amount of time.” Within two years of the policy taking effect, says Kaiser, just 3 percent of women with employer-sponsored insurance had out-of-pocket expenses for oral contraceptives (the most expensive and the most popular kind).
Millions of Americans will have a hard time falling or staying asleep tonight, and research says most of them will be women. “Insomnia is definitely more common in females, and it seems to begin fairly early on,” said Dr. Meir Kryger, a professor at the Yale School of Medicine who studies sleep. Sleep problems can appear in women as early as their teens or 20s, he said. Various research shows women are more likely than men to experience the sleep disorder. Women are about 1.5 times more likely to have insomnia, said Kryger, who has written several books on the topic, including “The Mystery of Sleep,” which was published in March.
In 1776, Abigail Adams asked her husband to “remember the ladies.”
Oh, if only Melania were so moved. Donald Trump could use the reminder. From the moment he announced his improbable campaign, Trump has played to his most conservative supporters by promising to severely restrict abortion rights, as well as limit access to affordable birth control. The battle has settled onto two fronts, including defunding Planned Parenthood, and—since a “repeal and replace effort” fell short—removing from the Affordable Care Act the mandate that requires employers to provide insurance coverage for contraceptives to their eligible workers. On the first front, Connecticut has vowed to fund Planned Parenthood, should the federal government pull away.
A genetic test that helps doctors determine how best to treat breast cancer—and whether chemotherapy is likely to help—is significantly more likely to be administered to white women than blacks or Hispanics, a Yale study has found. The test, called Oncotype Dx (ODx), uses gene expression to gauge how early-stage breast cancer is affecting patients’ gene activity. It uses the information to determine how likely cancer recurrence would be, and physicians and their patients can use that knowledge to decide how to proceed with treatment. Yale researchers retrospectively analyzed a group of more than 8,000 Connecticut women who were diagnosed with hormone receptor positive breast cancer between 2011 and 2013, and found “significant racial and ethnic disparities in use of this new gene test,” said study leader Dr. Cary Gross, a member of Yale Cancer Center and professor of medicine and epidemiology at Yale School of Medicine. “It reinforces that, at the same time we are investing in developing new treatments and new testing strategies and we’re promoting them with great excitement, we really need to double-down our efforts to eliminate disparity,” Gross said.
Low-income women in Connecticut who have just given birth and know they don’t want to get pregnant again anytime soon are now offered a long-acting birth control option postpartum. Medical providers say the policy by the U.S. Department of Health and Human Services will reduce the number of unplanned pregnancies, as well as lead to better maternal health outcomes by ensuring pregnancies are spaced a healthy length of time apart. Connecticut’s HUSKY program is one of 26 state Medicaid programs nationwide that reimburses hospitals for administering long-acting reversible contraception (LARC)—namely, intrauterine devices (IUDs) and subdermal implants—to Medicaid patients. HUSKY started reimbursing for the devices last year. “It’s a great thing,” said Dr. Elizabeth Purcell, an obstetrician and gynecologist practicing in Hartford.